Kymera Therapeutics KYMR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.23M-5.6% | -$86.98M-22.9% | -$82.18M-31.5% | -$76.61M-82.1% | -$65.58M-35.1% | ||
| $2.02M-1.3% | $2.03M+2.3% | $2.15M+8.2% | $2.08M+7.5% | $2.05M+40.2% | ||
| $16.01M+12.5% | $14.45M+4.7% | $15.8M+6.0% | $15.42M+7.5% | $14.23M+18.9% | ||
| —— | $1K— | $3.86M— | $0— | $0-100% | ||
| $8.82M+125% | -$1.49M-195% | -$267K-390% | -$4.13M-13,432% | $3.92M+5,123% | ||
| -$7.21M+38.3% | $13.66M+51.4% | —— | —— | -$11.69M+24.1% | ||
| $3.57M+228% | $5.13M— | $0+100% | $5.08M+257% | -$2.78M-192% | ||
| -$2.15M-410% | —— | -$290K+38.9% | —— | $694K+350% | ||
| -$34.37M-1,536% | —— | —— | $28.52M+219% | -$2.1M+74.6% | ||
| -$88.84M-12.2% | -$66.75M-8.0% | -$27.11M+46.0% | -$59.88M-39.5% | -$79.15M-99.9% | ||
| $434K-7.1% | $106K-88.7% | $181K— | $695K-85.2% | $467K-93.7% | ||
| $276.27M+230% | —— | $367.56M+24.2% | $58.25M-44.1% | $83.66M-80.2% | ||
| $133.86M+0.8% | —— | $132.44M-4.1% | $118.97M-4.4% | $132.74M+33.4% | ||
| -$142.84M-394% | -$394.4M— | -$235.3M-49.2% | $60.02M— | $48.62M+115% | ||
| $19.19M— | $0— | $0— | $0— | $0-100% | ||
| $425K+53.4% | $416K+42.0% | $419K-34.6% | $382K+8.5% | $277K-4.5% | ||
| $18.77M+7,175% | $705.22M+25,405% | $39.51M-84.3% | $245.73M+17,303% | $258K-99.9% | ||
| -$212.91M-603% | $244.07M+2,456% | -$222.9M-618% | $245.86M+1,050% | -$30.28M-84.1% | ||
| $65K-15.6% | $75K+21.0% | $83K+53.7% | $77K+87.8% | $77K+57.1% | ||
| —— | $964K-21.7% | $964K-21.7% | $964K-21.7% | $964K-21.7% | ||
| $0-100% | —— | —— | -$20M-6,016% | $19.05M+1,200% | ||
| -$1.36M-17.7% | -$1.33M— | -$1.3M— | -$1.26M-183% | -$1.15M-144% | ||
| -$615K+8.6% | -$596K+9.4% | -$708K-10.8% | -$689K-10.2% | -$673K-8.7% | ||
| —— | $4.5K+106% | $4.5K+106% | $4.5K+106% | $4.5K+106% | ||
| $3.57M+228% | $322K-89.8% | —— | $5.08M— | -$2.78M-192% | ||
| $133.86M+0.8% | —— | $132.44M-4.1% | $118.97M-4.4% | $132.74M+33.4% | ||
| —— | -$164.06M— | -$164.06M— | -$164.06M— | -$164.06M— | ||
| $19.19M+3,488% | $48.83M+2,146% | $4.55M-9.9% | $7.7M+1,124% | $535K-86.4% | ||
| $110K-69.2% | —— | $912K— | —— | $357K-70.4% | ||
| —— | $257K-62.5% | $257K-62.5% | $257K-62.5% | $257K-62.5% | ||
| -$89.27M-12.1% | -$66.85M-6.6% | -$27.29M+45.4% | -$60.58M-27.2% | -$79.62M-69.4% | ||
| -$89.27M-12.1% | -$66.85M-6.6% | -$27.29M+45.4% | -$60.58M-27.2% | -$79.62M-69.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kymera Therapeutics generate?
- Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
- What is Kymera Therapeutics's free cash flow?
- After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
- Where does Kymera Therapeutics's cash flow data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
